Greene Tweed Awarded 'Excellence in International Trade' at the 2024 East Midlands Chamber Business Awards
The regional accolade recognizes commitment to global expansion and customer support
LANSDALE, PA / ACCESSWIRE / November 8, 2024 / Greene Tweed, a global leader in advanced materials and high-performance solutions, has been honored as the Nottinghamshire "Excellence in International Trade" recipient of the 2024 East Midlands Chamber Business Awards, which celebrate the achievement and resilience of companies throughout the region.
The East Midlands Chamber plays a vital role in connecting, supporting, and championing businesses and communities across Derbyshire, Leicestershire and Nottinghamshire in the United Kingdom. The Nottinghamshire Business Awards recently celebrated outstanding achievements in the local business community, where winners across 13 categories were announced.
The "Excellence in International Trade" award specifically recognizes local businesses that excel in overseas trade. As one of five finalists in the category, Greene Tweed was selected for its robust growth strategy focused on international expansion, along with steady sales growth in recent years. Judges praised the company's clear passion for supporting its customer base, as demonstrated in its strong corporate culture and deep analytical insights.
"We truly appreciate this recognition by the East Midlands Chamber," said Tony Baldassarra, Greene Tweed Nottingham, UK Site Operations Leader. "The ‘Excellence in International Trade' award is a testament to our unwavering commitment to global trade compliance, and it reflects the team's dedication to collaboration with international partners to uphold high standards. Together, we can continue to drive excellence in our industry."
Recently, Greene Tweed's Nottingham facility received the ISO 14001:2015 Environmental Management System certification from BSI, a significant milestone in the company's global Sustainability Vision. As the first Greene Tweed location to obtain certification to this internationally recognized standard developed by the ISO (International Organization for Standardization), Nottingham has set the stage for the company's long-term goal to achieve ISO 14001 certification at plants worldwide.
Greene Tweed is also investing in its global manufacturing network to meet future industry needs, including a newly opened facility in Korea that increases capacity to deliver high-quality Chemraz® products at scale. As the company expands its global footprint, the Nottingham facility - which employs more than 150 members - will continue to play a key role in supporting sales, engineering, manufacturing, and quality across the UK, Europe, the Middle East and Africa.
###
About Greene Tweed
Greene Tweed is a leading global manufacturer of high-performance thermoplastics, composites, seals, and engineered components. For 160 years, we have served clients in semiconductor, oil and gas, aerospace, defense, chemical and pharmaceutical processing, and other industries where failure is not an option.
Greene Tweed products are sold and distributed worldwide. For additional information, call +1.215.256.9521, or visit our website at http://www.gtweed.com.
Contact Information
Sofia Doss
PR & Communications
sdoss@gtweed.com
SOURCE: Greene Tweed
View the original press release on newswire.com.
Greene Tweed
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom